Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell of lymphatic vessel | 14 studies | 30% ± 15% | |
non-classical monocyte | 13 studies | 28% ± 12% | |
endothelial cell | 11 studies | 29% ± 13% | |
classical monocyte | 10 studies | 20% ± 5% | |
macrophage | 9 studies | 31% ± 16% | |
microglial cell | 8 studies | 31% ± 11% | |
myeloid cell | 6 studies | 31% ± 13% | |
GABAergic neuron | 5 studies | 28% ± 8% | |
monocyte | 5 studies | 32% ± 10% | |
plasma cell | 4 studies | 43% ± 9% | |
oligodendrocyte precursor cell | 4 studies | 21% ± 6% | |
GABAergic interneuron | 3 studies | 19% ± 3% | |
epithelial cell | 3 studies | 34% ± 9% | |
glutamatergic neuron | 3 studies | 41% ± 15% | |
interneuron | 3 studies | 28% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 28% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 5129.68 | 652 / 653 | 99% | 45.30 | 596 / 605 |
breast | 99% | 2873.71 | 455 / 459 | 97% | 44.88 | 1082 / 1118 |
lung | 100% | 4147.32 | 578 / 578 | 95% | 35.24 | 1094 / 1155 |
esophagus | 98% | 4153.39 | 1419 / 1445 | 88% | 25.53 | 161 / 183 |
ovary | 100% | 7839.71 | 180 / 180 | 81% | 21.12 | 350 / 430 |
pancreas | 87% | 1203.14 | 284 / 328 | 91% | 25.13 | 162 / 178 |
brain | 78% | 1903.39 | 2052 / 2642 | 98% | 34.00 | 692 / 705 |
uterus | 100% | 1848.35 | 170 / 170 | 72% | 14.30 | 332 / 459 |
kidney | 87% | 1906.97 | 77 / 89 | 81% | 36.87 | 733 / 901 |
liver | 88% | 1608.60 | 199 / 226 | 71% | 12.64 | 290 / 406 |
adrenal gland | 98% | 2254.84 | 253 / 258 | 61% | 21.31 | 141 / 230 |
prostate | 99% | 2456.31 | 243 / 245 | 59% | 8.32 | 296 / 502 |
bladder | 100% | 1873.57 | 21 / 21 | 50% | 11.56 | 253 / 504 |
intestine | 99% | 3963.00 | 952 / 966 | 49% | 8.94 | 257 / 527 |
stomach | 79% | 2299.29 | 283 / 359 | 62% | 14.16 | 178 / 286 |
skin | 74% | 1340.98 | 1336 / 1809 | 44% | 6.69 | 208 / 472 |
adipose | 100% | 3670.31 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 8740.97 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2795.69 | 1331 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 28.39 | 40 / 45 |
peripheral blood | 83% | 11808.96 | 769 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 19.18 | 24 / 29 |
muscle | 82% | 1756.99 | 662 / 803 | 0% | 0 | 0 / 0 |
heart | 41% | 514.39 | 356 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.25 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030206 | Biological process | chondroitin sulfate biosynthetic process |
GO_0019319 | Biological process | hexose biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016020 | Cellular component | membrane |
GO_0050656 | Molecular function | 3'-phosphoadenosine 5'-phosphosulfate binding |
GO_0050659 | Molecular function | N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CHST15 |
Protein name | Alternative protein CHST15 Carbohydrate sulfotransferase 15 (EC 2.8.2.33) (B-cell RAG-associated gene protein) (hBRAG) (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase) (GalNAc4S-6ST) Carbohydrate sulfotransferase 15 |
Synonyms | BRAG GALNAC4S6ST KIAA0598 |
Description | FUNCTION: Sulfotransferase that transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the C-6 hydroxyl group of the GalNAc 4-sulfate residue of chondroitin sulfate A and forms chondroitin sulfate E containing GlcA-GalNAc(4,6-SO(4)) repeating units. It also transfers sulfate to a unique non-reducing terminal sequence, GalNAc(4SO4)-GlcA(2SO4)-GalNAc(6SO4), to yield a highly sulfated structure similar to the structure found in thrombomodulin chondroitin sulfate. May also act as a B-cell receptor involved in BCR ligation-mediated early activation that mediate regulatory signals key to B-cell development and/or regulation of B-cell-specific RAG expression; however such results are unclear in vivo. . |
Accessions | L8ECG4 ENST00000346248.7 [Q7LFX5-1] L8EAU1 Q7LFX5 A0A0D9SFZ3 ENST00000462406.1 ENST00000435907.6 [Q7LFX5-1] ENST00000628426.1 [Q7LFX5-2] |